NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
XFOR
X4 Pharmaceuticals, Inc.
There isn't enough reported data to score XFOR yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
XFOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
XFOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
XFOR PE Valuation
XFOR has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
XFOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XFOR's revenue to grow, with its earnings and profitability holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus XFOR down 662%.
XFOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.12 | -$8.32 |
| Q2 2025 | -$14.83 | -549% |
| Q1 2025 | $2.14 | +$22.24 |
| Q4 2024 | -$5.70 | +$11.40 |
| Q3 2022 | -$83.10 | +$27.90 |
| Q2 2022 | -$98.10 | +$16.20 |
| Q1 2022 | -$102.30 | +$12.60 |
| Q4 2021 | -$119.70 | -$27.00 |
XFOR is still losing money, but far less than before: $10.12 per share over the past year, against $119.70 at its worst in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over XFOR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over XFOR on profitability, with a higher operating margin.
XFOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +79% |
| Q2 2026 | $2.4M | +38% |
| Q1 2026 | $2.5M | +178% |
| Q4 2025 | $2.2M | +53% |
| Q3 2025 | $1.6M | +180% |
| Q2 2025 | $1.7M | +210% |
XFOR's revenue has grown year over year for 10 quarters in a row: $3M last quarter, up 79% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -714% | +1043 points |
| Q2 2026 | -683% | +821 points |
| Q1 2026 | -812% | +237 points |
| Q4 2025 | -1077% | +1413 points |
| Q3 2025 | -1757% | +4404 points |
| Q2 2025 | -1504% | -14133 points |
| Q1 2025 | -1049% | N/A |
| Q4 2024 | -2491% | N/A |
XFOR's operating margin was −714% last quarter, up 1043 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over XFOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XFOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | +$7.6M |
| Q2 2026 | -$20.8M | +$9.1M |
| Q1 2026 | -$19.6M | -$7.2M |
| Q4 2025 | -$15.5M | +$17.5M |
| Q3 2025 | -$27.8M | +$6.3M |
| Q2 2025 | -$29.9M | +$34.1M |
| Q1 2025 | -$12.4M | +$21.3M |
| Q4 2024 | -$33M | -$5.3M |
XFOR has burned cash in almost every quarter: −$76M over the past year, against −$103M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over XFOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
XFOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +180K shares |
| 1 year | +1607% | +119M shares |
| 3 years | +2149% | +121M shares |
| 5 years | +18192% | +126M shares |
| Available history | +18865% | +126M shares |
XFOR has 127M diluted shares, up 1607% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | $443,000 |
| Q4 2022 | — |
| Q4 2021 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
XFOR Net Leverage
XFOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
XFOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 34.5 | Neutral |
XFOR's weekly RSI is 44 (neutral) and its Stochastic is 35 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XFOR PE vs Healthcare Sector
| Metric | XFOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XFOR has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
XFOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 4.3% above |
| 20 week MA | $3.63 | 13% below |
| 50 week MA | $3.81 | 17% below |
| 100 week MA | $5.35 | 41% below |
| 200 week MA | $18.2 | 83% below |
XFOR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 83% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over XFOR on returns for 2026, with the stronger performance.
XFOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $325.8 | $210.3 | -35% |
| 2021 | $210.3 | $74.1 | -65% |
| 2022 | $74.1 | $25.8 | -65% |
| 2023 | $25.8 | $25.2 | -2.6% |
| 2024 | $25.2 | $24.1 | -4.1% |
| 2025 | $24.1 | $4.50 | -81% |
| 2026 YTD | $4.50 | $3.17 | -30% |
XFOR has finished every year since 2020 lower, and it's down 30% so far in 2026.